Although CDC6 as well as E2F1 and DHFR were, after correcting for platelet presence, significantly higher in patients with metastatic disease compared to patients with localized disease and healthy controls, these markers cannot be easily used to discriminate between healthy individuals and neuroblastoma patients at the individual level. This evidence concerns the gene CDC6 and neuroblastoma.